| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-12446SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-24863 | |||
| BSA Free | NBP2-24729SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27149 | |||
| BSA Free | NB100-56566SS | |||
| Azide and BSA Free | NBP2-27149SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19532SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-683-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-56726 | |||
| BSA Free | NB100-56722SS | |||
| Azide and BSA Free | NB100-56726SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-33337SS | |||
| Azide and BSA Free | NBP2-80656 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-77080SS | |||
![Immunohistochemistry-Paraffin: Goat Polyclonal AIF-1/Iba1 Antibody [NB100-1028] - AIF-1/Iba1 immunoreactivity in an FFPE section of mouse spleen. NB100-1028 was diluted to 1ug per mL and was left on tissue sections for 30m at room temperature. Secondary was horse anti goat HRP polymer. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-immunohistochemistry-paraffin-752024135211..jpg)
![Immunohistochemistry-Paraffin: Goat Polyclonal AIF-1/Iba1 Antibody [NB100-1028] - AIF-1/Iba1 immunoreactivity in an FFPE section of human tonsil. NB100-1028 was diluted to 1ug per mL and was left on tissue sections for 30m at room temperature. Secondary was horse anti goat HRP polymer. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-immunohistochemistry-paraffin-7520241463..png)
![Immunohistochemistry-Paraffin: Goat Polyclonal AIF-1/Iba1 Antibody [NB100-1028] - AIF-1/Iba1 immunoreactivity in an FFPE section of equine spleen. NB100-1028 was diluted to 1ug per mL and was left on tissue sections for 30m at room temperature. Secondary was equine anti goat HRP polymer. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-immunohistochemistry-paraffin-2852024102248..png)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Microglia proliferate in non‐APP mice upon peripheral immune challengeA, BIba‐1, Ki67, & DAPI staining in the cortex & hippocampus of wild‐type & Nlrp3−/− (5 & 15 months old). Microglia proliferate upon LPS injection (white arrows). Non‐microglia cells proliferation was observed as well (yellow arrows). Scale bar: 20 μm.CQuantification of microglial proliferation in cortex (left panel) & hippocampus (right panel) (mean of 5 ± SEM; two‐way ANOVA followed by Tukey's post hoc test, *P 1.5, FDR-corrected p1.5, FDR-corrected p<0.05) to identify GO terms, including inflammatory response (b). The volcano plot shows significant DEGs derived from the NanoString analysis of the brains of Plcg2 inactivation (PLCG2 inact, n=3) & WT (n=3) mice (1-month male) (c). Immunostaining of microglial markers with IBA1 (green) & P2RY12 (red) & quantification of percent area in brain sections of 1-month-old male WT & PLCG2 inact demonstrate unchanged microglial morphology & area coverage (d). GO gene ontology, BP biological process, DEGs differentially expressed genes, FDR false discovery rate Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35180881), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415483623.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Representative & quantitative immunohistochemistry of the peri-infarct cortex before the bregma (coordinate + 0.58) in normal WT, normal sEH KO, MCAO WT, MCAO sEH KO, MCAO with vehicle treatment & MCAO with AUDA treatment mice (n = 2 for normal groups, n = 5–6 for all groups subjected to MCAO). (A–F, S) The number of CD31-positive endothelial cells significantly increased in the sEH KO before & after MCAO & post-MCAO AUDA-treated mice, while (G–L) Note the increased phosphorylated TrkB (p-TrkB) immunoreactivity that partially co-localized with NeuN-positive neurons, particularly in the sEH KO & AUDA-treated mice (arrows) (T). The percentage of NeuN- & p-TrkB-positive double labeling in the neuronal population was significantly increased compared to that in the corresponding controls. (M–R, U–V) GFAP-positive astrogliosis & Iba1-positive microglial infiltration decreased in post-MCAO sEH KO & AUDA treatment groups relative to that in the corresponding controls. The scale bar represents 50 µm. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29311641), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415482273.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Representative & quantitative immunohistochemistry of the peri-infarct cortex before the bregma (coordinate + 0.58) in normal WT, normal sEH KO, MCAO WT, MCAO sEH KO, MCAO with vehicle treatment & MCAO with AUDA treatment mice (n = 2 for normal groups, n = 5–6 for all groups subjected to MCAO). (A–F, S) The number of CD31-positive endothelial cells significantly increased in the sEH KO before & after MCAO & post-MCAO AUDA-treated mice, while (G–L) Note the increased phosphorylated TrkB (p-TrkB) immunoreactivity that partially co-localized with NeuN-positive neurons, particularly in the sEH KO & AUDA-treated mice (arrows) (T). The percentage of NeuN- & p-TrkB-positive double labeling in the neuronal population was significantly increased compared to that in the corresponding controls. (M–R, U–V) GFAP-positive astrogliosis & Iba1-positive microglial infiltration decreased in post-MCAO sEH KO & AUDA treatment groups relative to that in the corresponding controls. The scale bar represents 50 µm. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29311641), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415483641.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Norgestrel reduces pro-inflammatory & promotes anti-inflammatory phenotypes in rd10 microglia.(A) RT-qPCR analysis detected similar levels of mRNAs encoding progesterone receptor membrane complexes 1 & 2 (PGRMC1, PGRMC2) & all three membrane progesterone receptor isoforms, alpha , beta & gamma (mPR alpha , mPR beta , mPR gamma ) in rd10 retinal microglial cells. Classical progesterone receptor (PR A/B) was not expressed. Actin, HPRT & GAPDH served as reference genes. (B) Immunolabeling confirmed the presence of these progesterone receptors in primary rd10 microglial cells. Hoechst (blue) staining reveals the cell nuclei. Scale bar represents 10μm. (C) Fluorescent microscopic images of primary rd10 microglia immunolabeled for (C) (i) markers of activation (CD68) & pro-inflammation (M1) (iNOS) & (C) (ii) anti-inflammatory activation (M2) (MRC1); after treatment with 20 μM Norgestrel over 24h. Norgestrel reduced pro-inflammatory & increased anti-inflammatory markers in rd10 microglia. Scale bar 10μm. (D) Quantification of fluorescence intensity of (D) (i) CD68 & iNOS & (D) (ii) MRC1 in primary rd10 microglial cultures following Norgestrel treatment over 24h. N = 8 mice, n = 4 technical replicates per group. (E) Nitrite concentration in the media of rd10 microglia in vitro treated with Norgestrel or vehicle over 24hr. Norgestrel significantly reduced nitrite release from rd10 microglia. N = 8 biological replicates, n = 2 technical replicates per sample. Results are presented as mean ± SEM (t-test, *p<0.05, ***p<0.005, ****p<0.001). Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0165197), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415482243.jpg)
![Immunohistochemistry: AIF-1/Iba1 Antibody [NB100-1028] - Temporal activation of caspase-8 in Iba1-positive myeloid cells. Frozen tissue sections from mice upon pMCAO (n = 9) were analyzed by immunohistochemistry for expression of active caspase-8 or for expression of the microglia/macrophage marker Iba1. The contralateral side to the ischemic area was used an internal control for each animal. A small increase in body size of Iba1 positive cells was detected in the peri-infarct area at 6 h, with larger increase in cell body & numbers of cells expressing Iba1 detected at 24 & 48 h post occlusion (a). Cleaved caspase-8 was detected at low levels at 6 h, but a significant increase in expression levels was observed at 24 & 48 h in the peri-infarct area, but not at the contralateral side (a). Double immunofluorescent staining revealed that increased active caspase-8 expression was localized in Iba1-positive cells (b). Scale bar represent 100 μm in IHC images (a) & 10 μm in IF images (b) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27566702), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-31020241548514.jpg)
![Western Blot: AIF-1/Iba1 Antibody [NB100-1028] - GM1 effects on brain microglia in vivo, after peripheral administration of LPS. A Schematic representation of in vivo administration of GM1 after LPS-induced systemic inflammation in mice (N = 5 per treatment). B Representative images of Iba-1 stained microglia in the cortex of control animals infused with vehicle (CTRL) or GM1 (CTRL + GM1), & in animals treated with LPS & subsequently infused with vehicle artificial cerebrospinal fluid (LPS) or GM1 (LPS + GM1). C Immunoblot in whole brain lysates & densitometric analysis show LPS-dependent increase in Iba 1 expression. D Cortical & striatal microglia (Iba-1+ cells) cell body area quantified with MetaXpress software. GM1 administration significantly decreases cell body area in the cortex, but not in the striatum. E IL-6 protein levels in whole mouse brain homogenate. aCSF, artificial cerebrospinal fluid. Bars show mean values ± STDEV. Two-way ANOVA with Tukey’s multiple comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34991625), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415485114.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - ABIN1 knockdown increases proinflammatory cytokine production & microglial activation. (a-b) Levels of the ABIN1 mRNA & protein were detected 24 h after reperfusion using RT-qPCR & western blot, respectively, to confirm the efficiency of ABIN1 gene knockdown (n = 5 rats per group). (c) ELISA was used to detect the concentrations of TNF-alpha , IL-1 beta & MCP-1 in the peri-infarct cortex at 24 h after reperfusion (n = 5 rats per group). (d) Microglial morphology was observed using immunofluorescence staining for Iba-1 (green) in the peri-infarct cortex at 24 h after reperfusion (n = 3 rats per group). Scale bar = 50 μm. (e & f) Quantification of microglia process endpoints & cell & process lengths/cell (∗∗P < 0.01 compared to the sham group; ##P < 0.01 compared to the MCAO/R group). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33110436), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415485133.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - SCF+G-CSF treatment increases TREM2 expression in the Iba1+ microglia/macrophages surrounding the 6E10+ senile plaques. (A) Representative confocal images of TREM2 (red), 6E10 (purple) & Iba1 (green) triple immunofluorescence staining in the brains of aged APP/PS1 mice. Blue: Nuclear counterstaining by DAPI. (B) Representative orthographic view of z-stack images (12 z-stacks with 1μm intervals) illustrates the location & interaction of TREM2 + cells (red) & 6E10+ A beta plaques (white) in the brains of aged APP/PS1 mice. (C) Quantification data show the percentage of TREM2+ area surrounding the 6E10+ A beta plaques (within 10μm from the border of the A beta plaques) in the brains of aged APP/PS1 mice with or without SCF+G-CSF treatment. (D) Representative orthographic view of z-stack images (12 z-stacks with 1μm intervals) displays the location & interaction of TREM2+/Iba1+ co-expressing cells (yellow) & 6E10+ A beta plaques (white) in the brains of APP/PS1 mice. (E) Quantification data show the percentage of TREM2+/Iba1+ co-expression area in the total of Iba1+ area in the vicinity of 6E10+ A beta plaques in the brains of aged APP/PS1 mice with or without SCF+G-CSF treatment. N=4-5. Mean ± SEM. * p<0.05 by Student’s t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33269098), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415482219.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - SCF+G-CSF treatment increases the association of Iba1+ microglia/macrophages with senile plaques & enhances uptake of 4G8+ A beta by the Iba1+ microglia/macrophages in the brains of aged APP/PS1 mice. (A) Representative confocal images illustrate the association of Iba1+ cells (green) with 4G8+ A beta plaques (red) in the brains of aged APP/PS1 mice. Blue: Nuclear counterstaining by DAPI. (B) Quantification of the percentage of Iba1+ area in/surrounding the 4G8+ A beta plaques in the brains of aged APP/PS1 mice with or without SCF+G-CSF treatment. (C) Representative 3-dimensional projected images reveal the overlapped (yellow) Iba1+ cells (green) with 4G8+ A beta (red) in the brains of aged APP/PS1 mice. The white arrows indicate the co-expression (yellow) of 4G8+ A beta & Iba1+ cells in the brains of aged APP/PS1 mice. (D & E) Representative orthographic view of z-stack images (12 z-stacks with 1μm intervals) shows the co-expression (yellow) of 4G8+ A beta (red) & Iba1+ cells (green) in the brains of aged APP/PS1 mice. (F) Quantification data present the percentage of 4G8+ A beta volume within the Iba1+ cells in the brains of aged APP/PS1 mice treated with or without SCF+G-CSF. N=4-5. Mean ± SEM. *p<0.05 by Student’s t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33269098), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415485142.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Representative & quantitative immunohistochemistry of the peri-infarct cortex before the bregma (coordinate + 0.58) in normal WT, normal sEH KO, MCAO WT, MCAO sEH KO, MCAO with vehicle treatment & MCAO with AUDA treatment mice (n = 2 for normal groups, n = 5–6 for all groups subjected to MCAO). (A–F, S) The number of CD31-positive endothelial cells significantly increased in the sEH KO before & after MCAO & post-MCAO AUDA-treated mice, while (G–L) Note the increased phosphorylated TrkB (p-TrkB) immunoreactivity that partially co-localized with NeuN-positive neurons, particularly in the sEH KO & AUDA-treated mice (arrows) (T). The percentage of NeuN- & p-TrkB-positive double labeling in the neuronal population was significantly increased compared to that in the corresponding controls. (M–R, U–V) GFAP-positive astrogliosis & Iba1-positive microglial infiltration decreased in post-MCAO sEH KO & AUDA treatment groups relative to that in the corresponding controls. The scale bar represents 50 µm. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29311641), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415485140.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Antibody-mediated Nogo-A blockade decreases the number of cells expressing TNF alpha without affecting the number of Iba1-positive monocytes.Cells expressing TNF alpha , Iba1, & CD68 were labeled on cryosections by immunofluorescence in 4 mouse retinae, 24 h after control IgG or 11C7 injection. a Retinal sections showed many TNF alpha -containing cells located in the inner retina, between the outer plexiform layer & the ganglion cell layer 1 day after control IgG injection. A majority of cells was positive for Iba1 & exhibited vesicular staining of the lysosomal protein CD68, indicating their active state. b The injection of 11C7 strongly attenuated TNF alpha & CD68 expression & to a lower extent the intensity of Iba1 in macrophages/microglia. c Quantification of the number of cells expressing TNF alpha & Iba1 suggesting potent & specific effects of 11C7 on TNF alpha cytokine reduction. Six sections were examined for each retina. Statistics: one-way ANOVA, Dunnett’s post hoc test, **P < 0.01; ****P < 0.0001. Scale bars = 50 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32029703), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415485131.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - SCF+G-CSF treatment increases TREM2 expression in the Iba1+ microglia/macrophages surrounding the 6E10+ senile plaques. (A) Representative confocal images of TREM2 (red), 6E10 (purple) & Iba1 (green) triple immunofluorescence staining in the brains of aged APP/PS1 mice. Blue: Nuclear counterstaining by DAPI. (B) Representative orthographic view of z-stack images (12 z-stacks with 1μm intervals) illustrates the location & interaction of TREM2 + cells (red) & 6E10+ A beta plaques (white) in the brains of aged APP/PS1 mice. (C) Quantification data show the percentage of TREM2+ area surrounding the 6E10+ A beta plaques (within 10μm from the border of the A beta plaques) in the brains of aged APP/PS1 mice with or without SCF+G-CSF treatment. (D) Representative orthographic view of z-stack images (12 z-stacks with 1μm intervals) displays the location & interaction of TREM2+/Iba1+ co-expressing cells (yellow) & 6E10+ A beta plaques (white) in the brains of APP/PS1 mice. (E) Quantification data show the percentage of TREM2+/Iba1+ co-expression area in the total of Iba1+ area in the vicinity of 6E10+ A beta plaques in the brains of aged APP/PS1 mice with or without SCF+G-CSF treatment. N=4-5. Mean ± SEM. * p<0.05 by Student’s t-test. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33269098), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415482237.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Representative & quantitative immunohistochemistry of the peri-infarct cortex before the bregma (coordinate + 0.58) in normal WT, normal sEH KO, MCAO WT, MCAO sEH KO, MCAO with vehicle treatment & MCAO with AUDA treatment mice (n = 2 for normal groups, n = 5–6 for all groups subjected to MCAO). (A–F, S) The number of CD31-positive endothelial cells significantly increased in the sEH KO before & after MCAO & post-MCAO AUDA-treated mice, while (G–L) Note the increased phosphorylated TrkB (p-TrkB) immunoreactivity that partially co-localized with NeuN-positive neurons, particularly in the sEH KO & AUDA-treated mice (arrows) (T). The percentage of NeuN- & p-TrkB-positive double labeling in the neuronal population was significantly increased compared to that in the corresponding controls. (M–R, U–V) GFAP-positive astrogliosis & Iba1-positive microglial infiltration decreased in post-MCAO sEH KO & AUDA treatment groups relative to that in the corresponding controls. The scale bar represents 50 µm. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29311641), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415482285.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - Representative & quantitative immunohistochemistry of the peri-infarct cortex before the bregma (coordinate + 0.58) in normal WT, normal sEH KO, MCAO WT, MCAO sEH KO, MCAO with vehicle treatment & MCAO with AUDA treatment mice (n = 2 for normal groups, n = 5–6 for all groups subjected to MCAO). (A–F, S) The number of CD31-positive endothelial cells significantly increased in the sEH KO before & after MCAO & post-MCAO AUDA-treated mice, while (G–L) Note the increased phosphorylated TrkB (p-TrkB) immunoreactivity that partially co-localized with NeuN-positive neurons, particularly in the sEH KO & AUDA-treated mice (arrows) (T). The percentage of NeuN- & p-TrkB-positive double labeling in the neuronal population was significantly increased compared to that in the corresponding controls. (M–R, U–V) GFAP-positive astrogliosis & Iba1-positive microglial infiltration decreased in post-MCAO sEH KO & AUDA treatment groups relative to that in the corresponding controls. The scale bar represents 50 µm. *p < 0.05, **p < 0.01, ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29311641), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415482247.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NB100-1028] - The presence or absence of TRPV1 influences microglial pathophysiological changes in recurrent febrile seizures mice. (A) Images of the cortex immunostained for the microglial marker Iba-1 (visualized in green FITC) & the lysosomal marker CD68/ED1 (visualized in red Alexa Fluor 594) & DAPI (visualized in blue) 5 days after rFS from wild type (WT) & TRPV1−/− mice (Scale bars: 50 μm). (B,C) Bar graph of quantification of Iba1+(B) & Iba1+ ED1+(C) in 5 days after rFS mice cortex. (D) Representative photomicrographs of different microglial morphological subtypes including resting/ramified (Ram), hypertrophic/intermediate (Inter) & round/ameboid (Amoeboid; Scale bars: 5 μm). (E) Quantification of relative percentage of microglia with different morphologies in the cortex of WT & TRPV1−/− mice (n = 6 per groups, **p < 0.01, ***p < 0.001, two-way ANOVA followed by Tukey’s multiple comparisons). (F–H) Representative Immunoblot bands (F) & densitometric analysis of Iba1 expression (G) & ED1 expression (H) were significantly increased in rFS from WT mice than in TRPV1−/− mice. Data were presented as means ± SEM, n = 6 per groups, *p < 0.05, **p < 0.01, ***p < 0.001, two-way ANOVA followed by Tukey’s multiple comparisons. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31680864), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-310202415482254.jpg)
![Immunohistochemistry-Frozen: Goat Polyclonal AIF-1/Iba1 Antibody [NB100-1028] - AD Mouse Model. FxFr:10 µm thickness 1:200. Secondary antibody AF647. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-immunohistochemistry-frozen-4122024105512..jpg)
![Immunohistochemistry: Goat Polyclonal AIF-1/Iba1 Antibody [NB100-1028] - Pax5 and Iba1 immunoreactivity in a formalin fixed paraffin embedded classic Hodgkin's lymphoma biopsy. Formalin fixed paraffin embedded sections were deparaffinized and rehydrated. Sections then underwent heat induced epitope retrieval in a citrate-based solution for 20min in a food steamer. Sections were cooled, then blocked in phosphate buffered saline containing 0.2% Triton-X100 and 10% normal donkey serum for 1h at room temperature. Sections were then incubated with the primary antibody for 16h at room temperature. The following day slides were washed three times with PBS containing 0.05% Tween-20. Sections were then incubated with donkey anti-goat (647 conjugate) at 5ug per mL for 45min at room temperature. Slides were then washed as above and mounted with a coverslip. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-1028_goat-polyclonal-aif-1-iba1-antibody-immunohistochemistry-332025111028..jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Western blot analysis of TXNIP & NLRP3 protein expression in cultured HK-2 cells treated by normal glucose (5.5 mM), high glucose (30 mM), & NG + mannitol, respectively, for 72 hours, then following 4 hours of hypoxia & 2 hours of reoxygenation in HK-2 cells under high glucose stimulation with or without TXNIP siRNA & RES treatment, respectively. Representative blots (a) & quantitative analysis of Western blots for TXNIP (c) & NLRP3 (d), activity of caspase-1 (e), level of IL-1 beta (f), & Western blot of TXNIP gene knockdown in HK-2 cells (b). The data in (c–f) are means ± SE (n = 5). #P 0.05; *p 0.05; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113536.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Exercise training prevents HFD-induced upregulation of cardiac pyroptosis. Western blotting was performed to determine the components of inflammasome complex & pyroptosis in the left ventricle of mice hearts. (A) HFD-fed obese mice show upregulation of the NLRP3 inflammasome in the left ventricle, which is prevented by exercise training. (B) Apoptosis-associated speck adaptor protein (ASC) that assembles with NLRP3 & caspase-1 to make inflammasome complex is elevated in the heart of obese mice but attenuated by exercise training. (C) Exercise training prevents HFD-induced upregulation of cardiac caspase-1. (D) Expression of IL-1 beta , which is upregulated by HFD, is normalized by exercise training. All values are expressed as mean ± SEM with dots of different shape representing each animal in a group. One-way ANOVA & Tukey’s post-hoc test were used for statistical analysis. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31835893), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241612224.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - NLRP3 knockdown decreases corneal inflammation & suppressed neutrophil infiltration in mouse C. albicans keratitis. The C57BL/6 mice were subconjunctivally injected with 6 μL (4 × 108 PFU) of the Ad-GFP-shRNA or Ad-NLRP3-shRNA suspension 3 days before inoculation with 1 × 106 CFU C. albicans or with 5μL sterile PBS after the corneas were scratched. The mouse corneas or eyeballs were collected at 3 dpi & subjected for further detection. RT-qPCR analysis (A), western blot (B) & immunofluorescence staining (C) were used to verify the gene knockdown efficiency of Ad-NLRP3-shRNA (n = 3). Scale bar = 20 μm; magnification 400×. (D) Micrographs of Ad-GFP-shRNA & Ad-NLRP3-shRNA-pretreated mouse corneas were photographed at 3dpi. (E) Clinical score of the infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3-shRNA (n = 10). (F) Immunofluorescence staining was performed to assess the levels of neutrophils recruitment in mouse corneas after Ad-GFP-shRNA & Ad-NLRP3-shRNA pretreatment (n =3). Scale bar = 50 μm; magnification 200×. FK: fungal keratitis. All values are presented as mean ± SEM. **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241613619.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - NLRP3 knockdown decreases corneal inflammation & suppressed neutrophil infiltration in mouse C. albicans keratitis. The C57BL/6 mice were subconjunctivally injected with 6 μL (4 × 108 PFU) of the Ad-GFP-shRNA or Ad-NLRP3-shRNA suspension 3 days before inoculation with 1 × 106 CFU C. albicans or with 5μL sterile PBS after the corneas were scratched. The mouse corneas or eyeballs were collected at 3 dpi & subjected for further detection. RT-qPCR analysis (A), western blot (B) & immunofluorescence staining (C) were used to verify the gene knockdown efficiency of Ad-NLRP3-shRNA (n = 3). Scale bar = 20 μm; magnification 400×. (D) Micrographs of Ad-GFP-shRNA & Ad-NLRP3-shRNA-pretreated mouse corneas were photographed at 3dpi. (E) Clinical score of the infected corneas pretreated with Ad-GFP-shRNA & Ad-NLRP3-shRNA (n = 10). (F) Immunofluorescence staining was performed to assess the levels of neutrophils recruitment in mouse corneas after Ad-GFP-shRNA & Ad-NLRP3-shRNA pretreatment (n =3). Scale bar = 50 μm; magnification 200×. FK: fungal keratitis. All values are presented as mean ± SEM. **p < 0.01; ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113526.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - Heat-killed C. albicans (HKCA) activates NLRP3 inflammasome & induces pyroptosis in human corneal epithelial cells (HCECs). (A) The mRNA expression of NLRP3 in HCECs challenged with HKCA at an MOI of 1:500, 1:50, 1:5, 2:1, or 20:1 respectively for 4 hours was evaluated by RT-qPCR (n = 5). (B–D) The mRNA & protein expression of NLRP3 in HCECs exposed to HKCA (MOI = 20) for 0 (control), 2, 4, 8, 12, or 24 h (n = 3). (E) NLRP3 fluorescence intensity was evaluated using immunofluorescent staining for different times (12–36 h). (n = 3; Scale bar = 20 μm; magnification 400×). (F) Lactate dehydrogenase (LDH) of HCECs treated with HKCA (MOI = 20) for 24 h (n = 6). (G) The mRNA levels of ASC, CASP1, IL-1 beta , IL-18 & GSDMD in HCECs exposed to HKCA (MOI = 20) for different times (n = 3). (H,I) The protein expression of pyroptosis-related proteins (ASC, cleaved CASP1, N-GSDMD, cleaved IL-1 beta & cleaved IL-18) was examined by western blot (n = 3). CASP1: caspase-1; Clv-CASP1: cleaved CASP1; Clv-IL-1 beta : cleaved IL-1 beta ; Clv-IL-18: cleaved IL-18; N-GSDMD: cleaved p30 form of GSDMD. All values are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. control group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35463001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241611470.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - The P2X7R inhibitor suppressed PA-induced inflammation, fibrosis & apoptosis in cardiomyocytes. (A) Cell viability was assessed by the CCK8 assay. H9c2 myocytes were incubated in a medium with A438079 at 0–80 μM for 12 h, & cells without A438079 treatment served as the control. (B) H9c2 myocytes were incubated in a medium with PA at 0–800 μM for 24 h, & cells without PA treatment served as the control. (C) Concentrations of IL-1 beta in cell culture supernatants were detected by ELISA. (D) Representative Western blot analysis of P2X7R, NLRP3 inflammasome, collagen I, MMP9, TGF-beta , caspase-1, caspase-3, Bax, & Bcl-2. (E) The protein semiquantification is shown for P2X7R, NLRP3 & caspase-1. (F) The protein semiquantification is shown for collagen I, MMP9 & TGF-beta . (G) The protein semiquantification is shown for caspase-3, Bax, & Bcl-2. (H) The percentages of TUNEL-positive cells are shown. (I) Representative images of TUNEL stained H9c2 myocytes. CON, H9c2 myocytes without any treatment; PA, H9c2 myocytes treated with 200 μM PA for 24 h; PA + A438079, H9c2 myocytes pretreated with A438079 for 12 h, & then treated with 200 μM PA for 24 h. ∗p < 0.05 versus the CON group, #p < 0.05 versus the HFD group. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31681001), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241613631.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP2-12446] - STZ-induced diabetes induces TXNIP expression & NLRP3 inflammasome activation following I/R 48. TXNIP expression was examined by IHC (a), representative blots (b), & quantitative analysis of Western blots for TXNIP (c), NLRP3 (d) & pro-caspase-1 & cleaved caspase-1 (e-f), & release of IL-1 beta & IL-18 by ELISA (g-h). The data in (c–h) are means ± SE (n = 5). ★P < 0.05 versus NS group; #P < 0.05 versus DS group; ▲P < 0.05 versus NI/R group; &P < 0.05 versus DI/R group. NS & DS: nondiabetic & STZ-induced diabetic rats were subjected to sham operation. NI/R & DI/R: nondiabetic & STZ-induced diabetic rats were subjected to 25 min ischemia followed by 48 h reperfusion. DI/R-RES: STZ-induced diabetic rats that underwent I/R were treated with RES (10 mg/kg, ip daily) for 7 consecutive days before renal ischemia-reperfusion. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/27867451), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-12446_rabbit-polyclonal-nlrp3-nalp3-antibody-310202416113521.jpg)
![Simple Western: TLR9 Antibody (26C593.2) [NBP2-24729] - Lane view shows a specific band for TLR9 in 0.5 mg/ml of Ramos lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system. Image using the Azide Free format of this antibody.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Simple-Western-NBP2-24729-img0029.jpg "Simple Western: TLR9 Antibody (26C593.2) [NBP2-24729] - Lane view shows a specific band for TLR9 in 0.5 mg/ml of Ramos lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system. Image using the Azide Free format of this antibody.")
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR9 protein on epithelial cells. HNEC, Detroit-562 and FaDu were stained intracellularly with PE-Ab against TLR9 (open histograms) or appropriate isotype control (shaded histograms) and analyzed by flow cytometry. Representative pictures from one out of three independent experiments are shown. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0098239), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0025.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR-9 protein in HB cells before and after 48 hr of transfection. Beta-actin was used as an internal control. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092748) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Knockdown-Validated-NBP2-24729-img0031.jpg)
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Analysis of colonic LP or peritoneal cavity (PerC) of normal mice were evaluated by flow cytometry. B cells were intracellularly stained with the anti-TLR9 antibody after the cell surface staining with anti-B220 and CD5 antibodies, and examined using flow cytometry. N = 3, performed twice. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0146191) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0027.jpg)
![Immunocytochemistry/Immunofluorescence: TLR9 Antibody (26C593.2) [NBP2-24729] - Cbl-b is required for the endocytic transit of TLR9. Representative confocal microscopic images of splenocytes from mice with indicated genotypes. For experiments, cells were stimulated through the BCR (green) for 30 minutes then fixed and stained for TLR9 (blue) and Lamp-1 (red)(n = 3). Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0089792) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Immunocytochemistry-Immunofluorescence-NBP2-24729-img0032.jpg)
![Immunohistochemistry-Paraffin: TLR9 Antibody (26C593.2) [NBP2-24729] - Monkey retina tissue. Image from verified customer review.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Immunohistochemistry-Paraffin-NBP2-24729-img0023.jpg)
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Gating strategy for the detection of TLR-7 and -9 in B cell subsets. PBMC were isolated from whole blood and stained for surface markers before cells were fixed, permeabilised and stained for TLR-9. FSC and SSC were first used to gate out debris and SSC-A and SSC-H was utilized to eliminate duplicates. Further gating was done on CD45 and CD19, to target B cells. To separate between the different B cell populations, we gated on CD27 and IgD (D), followed by TLR-9 expression on these subsets. Data from one representative patient is shown. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0120383) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0028.jpg)
![Western Blot: TLR9 Antibody (26C593.2) [NBP2-24729] - Analysis of TLR9 in A) human PBMC, B) human intestine, C) mouse intestine, and D) rat intestine tissue lysates using this antibody at a dilution of 3 ug/ml.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Western-Blot-NBP2-24729-img0033.jpg)
![Flow Cytometry: TLR9 Antibody (26C593.2) [NBP2-24729] - Expression of TLR9 on turbinate epithelial cells from healthy controls compared to turbinate and polyp epithelial cells from patients with CRSwNP, n = 5 (A). Intracellular staining for TLR9 (open histogram, black line) and isotype control (filled histogram) on turbinate epithelial cells from a healthy control (B), turbinate epithelial cells (C) and polyp epithelial cells from a patient (D), analysed using flow cytometry. Results are presented as mean +/- SEM, **P<0.01. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0105618) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR9-Antibody-26C593-2-Flow-Cytometry-NBP2-24729-img0030.jpg)
![Dual RNAscope ISH-IHC: TLR4 Antibody (76B357.1) [NB100-56566] - FFPE tissue sections of human tonsil were probed for TLR4 mRNA (ACD RNAScope Probe, ACD catalog # 311281; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Mouse Monoclonal (Novus Biologicals catalog # NB100-56566) at 5ug/mL with 1 hour incubation at room temperature followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Dual-RNAscope-ISH-IHC-NB100-56566-img0036.jpg "<b>Orthogonal Strategies Validation. </b>Dual RNAscope ISH-IHC: TLR4 Antibody (76B357.1) [NB100-56566] - FFPE tissue sections of human tonsil were probed for TLR4 mRNA (ACD RNAScope Probe, ACD catalog # 311281; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Mouse Monoclonal (Novus Biologicals catalog # NB100-56566) at 5ug/mL with 1 hour incubation at room temperature followed by incubation with anti-mouse IgG VisUCyte HRP Polymer Antibody (Catalog # VC001) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes.")
![<b>Orthogonal Strategies Validation. </b>Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using the Alexa Fluor (R) 647 conjugate of NBP2-27149. TLR4 expression on monocytes from human peripheral blood. PBMC were stained in a 2 color flow test, with CD14 PE version of this antibody and 1 ug of either isotype control (left) or TLR4-Alexa Fluor 647 (right). PPI negative, CD14+ cells were gated for analysis.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0024.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. Double-stained immunofluorescence for TLR4 (green) and vimentin (red) in normal (I), adenoma (II), and colon adenocarcinoma (III) (10x). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-NB100-56566-img0040.jpg)
![Western Blot: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using 2 ug/mL on (A) human intestine and 6 ug/mL on (B) mouse intestine and (C) rat intestine lysate.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Western-Blot-NB100-56566-img0018.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. IHC staining of colon adenocarcinoma for TLR4, vimentin, and alpha-SMA (40x). Staining co-localizes to the pericryptal space, confirming the signal arises from pericryptal myofibroblasts. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-NB100-56566-img0041.jpg)
![Flow (Intracellular): TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using PE conjugate of NBP2-27149. An intracellular stain was performed on Jurkat cells with TLR4 antibody (76B357.1) NBP2-27149PE (blue) and an isotype control MAB004 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Intracellular-NB100-56566-img0025.jpg)
![Immunocytochemistry/Immunofluorescence: TLR4 Antibody (76B357.1) [NB100-56566] - RH-30 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-TLR4 Antibody (76B357.1) NB100-56566 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunocytochemistry-Immunofluorescence-NB100-56566-img0042.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Immunofluorescent staining of TMAs. Representative tissue cores from normal (I), adenomatous polyps (II), and CRC (III and IV) are shown. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-NB100-56566-img0037.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of rat salivary gland tissue section at 1:100 dilution. The antibody generated a membrane-cytoplasmic staining in the tissue with stronger signal in ductal epithelial cells.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0015.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Tissue section of normal human skin stained with antibody at 5 ug/mL. Membrane-cytoplasmic immunopositivity of TLR4 was primarily observed in the pigmented basel cells and the adjacent keratinocytes in the epidermal layer.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0013.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on RH30 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0045.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human skin stained with at 5 ug/mL, peroxidase-conjugate and DAB chromogen. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0007.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of TLR4 in FFPE human colon tissue using an isotype control (top) and NB100-56566 (bottom) at 5 ug/mL.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0016.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human testis tissue stained with antibody at 5 ug/mL.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Paraffin-NB100-56566-img0017.jpg)
![Immunohistochemistry-Frozen: TLR4 Antibody (76B357.1) [NB100-56566] - This image is TLR4(green) and nucleus(blue) at area postrema of the adult male mouse brain, x20 magnification. Primary antibody diluted 1:500. IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Immunohistochemistry-Frozen-NB100-56566-img0032.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of formaldehyde fixed THP-1 cells (human monocytic leukemia cells) using 2 ug/10^6 cells TLR4 antibody (clone 76B357.1) with detection employing a donkey anti-mouse IgG (H+L) cross adsorbed secondary antibody, (DyLight 488 conjugated). Isotype control samples incubated with mouse IgG2b isotype control antibody were processed in parallal under the same assay conditions.](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0031.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Jurkat cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0043.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Raw264.7 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/TLR4-Antibody-76B357-1-Flow-Cytometry-NB100-56566-img0044.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Increased toll‐like receptor 4 (TLR4) expression in the myocardium of chronic heart failure (CHF) rats. (A) TLR4 mRNA levels in infarct & remote myocardium of sham & CHF rats (n = 6/group). (B) Representative Western blot images & (C) quantification of TLR4 proteins in infarct & remote myocardium of sham & CHF rats (n = 4/group). (D) Representative immunohistochemistry images of heart sections stained with TLR4 (green) & CD45 (red). The yellow box indicates the enlarged area shown on the right (data are means ± SD, *P < 0.05, **P < 0.01 versus respective sham). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26290459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241539724.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR3/4 expression in mice subjected to myocardial ischaemia (MI). The siRNA against FOXC1 (si‐FOXC1) or FOXC1 adenovirus (Ad‐FOXC1) was injected into the left ventricle just after LAD ligation to generate FOXC1 knockdown (A) or FOXC1 overexpression (B), & the negative control (NC) siRNA & Ad‐GFP served as control, respectively. The mRNA (upper panel) & protein (middle & lower panel) levels of TLR3/4 were determined after 2 wk. Data are means ± SEM aP < .05, AP < .01 vs respective MI Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415345314.jpg)
![Immunohistochemistry: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Representative images of immunohistochemical staining of pancreatic adenocarcinoma upregulated factor (PAUF) & toll-like receptor 4 (TLR4) in human ovarian cancer specimens. The top row (A,B) represents normal ovarian tissue, middle row (C,D) shows immunoreactivity of ovarian carcinomas & the bottom row (E,F) indicates immunonegativity of ovarian caricinoma. The stromal cells of normal ovarian tissue show immunonegativity for PAUF & TLR4. The scale bar represents 100 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30111860), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415293340.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Increased toll‐like receptor 4 (TLR4) expression in the surviving cardiomyocytes of chronic heart failure (CHF) rats. (A) Representative immunofluorescent images of TLR4 in cardiomyocytes isolated from sham & CHF rats. (B) TLR4 mRNA levels in cardiomyocytes isolated from sham & CHF rats. (C) Representative Western blot images & (D) quantification of TLR4 proteins in cardiomyocytes isolated from sham & CHF rats (data are means ± SD, n = 6/group, **P < 0.01 versus sham). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26290459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415175298.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Up‐regulation of FOXC1 & TLR3/4 protein levels under myocardial ischaemia. Representative Western blot images & quantitative data for FOXC1, TLR3 & TLR4 proteins in ischaemia models of mice (A), H9c2 cells (B) & NRVMs (C) are shown herein. Validation data of the antibodies for TLR3 & TLR4 are shown in Figure S1. Data are means ± SEM. n = ~4‐5/group. P values from the one‐way ANOVAs: 0.018 (TLR3 protein in mice), .002 (TLR4 protein in mice) & 0.006 (FOXC1 protein in mice). aP < .05, AP < .01 vs control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241534393.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - (a) Cell viability of MM cells exposed to increasing doses of LPS for 24 h. (b) Immunoblotting analysis of TLR4 protein expression levels in H929 & L363 cell lines after incubation with various LPS concentrations. Probing with beta -ACTIN was used as total protein loading reference. (c) Flow cytometry analysis for TLR4 expression of MM cell lines before & after exposure to 1 μg/ml LPS for 24 h. (d) Cell viability of MM cell lines pre-treated with 0.5 μg/ml TLR4 inhibitor for 24 h before stimulation with LPS for 24 h. (e) Cell vViability of H929 & JJN3 cell lines exposed to increasing concentrations of TLR4 inhibitor for 48 h. beta -ACTIN probing was used as reference for total protein input. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415304291.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR3/4 expression in mice subjected to myocardial ischaemia (MI). The siRNA against FOXC1 (si‐FOXC1) or FOXC1 adenovirus (Ad‐FOXC1) was injected into the left ventricle just after LAD ligation to generate FOXC1 knockdown (A) or FOXC1 overexpression (B), & the negative control (NC) siRNA & Ad‐GFP served as control, respectively. The mRNA (upper panel) & protein (middle & lower panel) levels of TLR3/4 were determined after 2 wk. Data are means ± SEM aP < .05, AP < .01 vs respective MI Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415371989.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Up‐regulation of FOXC1 & TLR3/4 protein levels under myocardial ischaemia. Representative Western blot images & quantitative data for FOXC1, TLR3 & TLR4 proteins in ischaemia models of mice (A), H9c2 cells (B) & NRVMs (C) are shown herein. Validation data of the antibodies for TLR3 & TLR4 are shown in Figure S1. Data are means ± SEM. n = ~4‐5/group. P values from the one‐way ANOVAs: 0.018 (TLR3 protein in mice), .002 (TLR4 protein in mice) & 0.006 (FOXC1 protein in mice). aP < .05, AP < .01 vs control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415291964.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Up‐regulation of FOXC1 & TLR3/4 protein levels under myocardial ischaemia. Representative Western blot images & quantitative data for FOXC1, TLR3 & TLR4 proteins in ischaemia models of mice (A), H9c2 cells (B) & NRVMs (C) are shown herein. Validation data of the antibodies for TLR3 & TLR4 are shown in Figure S1. Data are means ± SEM. n = ~4‐5/group. P values from the one‐way ANOVAs: 0.018 (TLR3 protein in mice), .002 (TLR4 protein in mice) & 0.006 (FOXC1 protein in mice). aP < .05, AP < .01 vs control Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241530423.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - TLR4 mRNA (a1) & protein (a2) expression in MM cell lines. (b) TLR4 mRNA expression of 16 CD138+ selected MM patients as determined by PCR & agarose gel electrophoresis. Probing with beta -ACTIN was used as total protein loading reference, whereas beta -ACTIN gene expression was used as reference for RNA input. beta -ACTIN probing & beta -ACTIN mRNA expression were used as reference for total protein & mRNA input, respectively. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241534332.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR expression. H9c2 cells were transfected with adenovirus or siRNA to overexpress or knock down FoxC1, with GFP adenovirus (Ad‐GFP) & negative control (NC) siRNA serving as control, respectively. A, FoxC1 overexpression increased Tlr3/4 mRNA & protein levels, under both control & ischaemic conditions. P values from the one‐way ANOVAs: <.001 (TLR3 mRNA), .002 (TLR4 mRNA), <.001 (FOXC1 mRNA), <.001 (TLR3 protein), <0.001 (TLR4 protein) & <.001 (FOXC1 protein). B, FoxC1 knockdown decreased Tlr3/4 mRNA & protein levels. P values from the one‐way ANOVAs: .001 (TLR3 mRNA), <.001 (TLR4 mRNA), <.001 (FOXC1 mRNA), .002 (TLR3 protein), <.001 (TLR4 protein) & <.001 (FOXC1 protein). C, FoxC1 overexpression up‐regulated the mRNA expression of multiple Tlr subtypes. P values from the one‐way ANOVAs: .022 (TLR1 mRNA), .047 (TLR2 mRNA), .002 (TLR3 mRNA), .013 (TLR4 mRNA), .039 (TLR5 mRNA), .003 (TLR6 mRNA), .203 (TLR7 mRNA), .078 (TLR8 mRNA) & .009 (TLR9 mRNA). Data are means ± SEM of 4 independent experiments. aP < .05, AP < .01 vs. control; bP < .05, BP < 0.01 vs. ischaemia Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241683915.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Immunofluorescent staining of TMAs. A) Low power (10x) view of NCI TMA slide stained for TLR4 (green), intestinal epithelium/pan-cytokeratin (red), & nucleus/DAPI (blue). B) Representative tissue cores from normal (I), adenomatous polyps (II), & CRC (III & IV) are shown. C & D) TLR4 staining score by tissue type & tissue compartment (stroma vs epithelium) are shown. C) TLR4 staining in the tumor stroma had a significantly higher average intensity score for stages 3 & 4 CRC when compared to stage 1. D) TLR4 staining in the tumor epithelium had a significantly higher average intensity score for stages 2 & 3 when compared to stage 1. E) TLR4 staining by compartment broken down by stage (controlling for grade) & grade (controlling for stage). Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415525244.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Immunofluorescent staining of TMAs. A) Low power (10x) view of NCI TMA slide stained for TLR4 (green), intestinal epithelium/pan-cytokeratin (red), & nucleus/DAPI (blue). B) Representative tissue cores from normal (I), adenomatous polyps (II), & CRC (III & IV) are shown. C & D) TLR4 staining score by tissue type & tissue compartment (stroma vs epithelium) are shown. C) TLR4 staining in the tumor stroma had a significantly higher average intensity score for stages 3 & 4 CRC when compared to stage 1. D) TLR4 staining in the tumor epithelium had a significantly higher average intensity score for stages 2 & 3 when compared to stage 1. E) TLR4 staining by compartment broken down by stage (controlling for grade) & grade (controlling for stage). Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241553739.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Effect of Cucumis sativus L. extract (CSE) on LPS induced TLR4 expression. a Expression of TLR4 mRNA in pAECs treated with LPS (10 μg/ml) for different time (1, 7, 24 h) in the presence or absence of increasing doses of CSE (0.02; 0.2; 2 mg/ml). mRNA expression of TLR4 is determined by quantitative PCR; relative expression was calculated as fold of change in respect to the control cells & error bar represents the range of relative expression. Different letters above the bars indicate significant differences. b Representative Western Blot of TLR4 & relative housekeeping alpha -tubulin were reported. c Expression of TLR4 protein in pAECs treated with LPS (10 μg/ml) in the presence or absence of increasing doses CSE (0.02; 0.2; 2 mg/ml); data shown are representative of at least three independent experiments & represent the mean ± SEM. Different letters above the bars indicate significant differences (p < 0.05 ANOVA post hoc Tukey’s test) Image collected & cropped by CiteAb from the following publication (//bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-018-2254-1), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241553730.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Activation receptors are shed during intrinsic repair. (A) BMDM were unchallenged (control) or challenged with 500 HU/mL SLO WT, PFO or an equivalent mass of SLO ML for 10 min at 37 °C & centrifuged at 2000 × g for 5 min to yield cell pellet (C). Supernatants were spun at 100,000xg for 40 min at 4 °C to collect the high speed supernatant (S) & microvesicle pellet (M). Samples were solubilized at 95 °C in SDS-sample buffer, resolved by SDS-PAGE & transferred to nitrocellulose. Portions of the blot were probed with 6D11 anti-SLO, anti-IFN gamma R1, 4B4F12 anti-CD14, 76B357.1 anti-TLR4, O91B8 anti-MyD88, 1H4B01 anti-Trif, EPR4477 anti-Alkaline Phosphatase, MANLAC-4A7 anti-Lamin A/C, & AC-15 anti-beta -Actin antibodies followed by relevant secondary antibodies & ECL. Full-length blots are presented in Supplementary Figure S1. (B) BMDM were challenged with 500 HU/mL SLO WT or SLO N402C, SLO ML at equivalent mass to SLO WT, or SLO N402E at equivalent mass to SLO N402C for 10 min. Cell pellets (C), high speed supernatants (S) & microvesicles (M) were isolated as in (A) & probed with 6D11 anti-Streptolysin O, 76B357.1 anti-TLR4, O91B8 anti-MyD88, 1H4B01 anti-Trif, EPR4477 anti-Alkaline Phosphatase, MANLAC-4A7 anti-Lamin A/C, & AC-15 anti-beta -Actin antibodies. Full-length blots are presented in Supplementary Figure S2. The blots are representative of at least 3 independent experiments. Image collected & cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-24955-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415535180.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. A) CRCs were separated into two groups representing low- & high- stromal expression of TLR4 by IHC staining. In normal tissue, stromal TLR4 expression is mainly due to macrophages (Green: TLR4, Red: CD68, Merge: TLR4 + CD68 + DAPI (blue)). Conversely, in CRCs increased vimentin & decreased CD68 staining in the pericryptal space confirm that this signal was due to pericryptal myofibroblasts & not related to tumor-associated macrophages. B) Double-stained immunofluorescence for TLR4 (green) & vimentin (red) in normal (I), adenoma (II), & colon adenocarcinoma (III) (10×). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. C) IHC staining of colon adenocarcinoma for TLR4, vimentin, & alpha -SMA (40×). Staining co-localizes to the pericryptal space, confirming the signal arises from pericryptal myofibroblasts. D, E, & F) An increase in IHC staining for alpha -SMA & vimentin was noted in CRCs when compared to normal or low grade dysplasia. A decrease in staining for CD68 positive macrophages was observed with higher degrees of dysplasia. Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241553724.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - (a1) Q-PCR assay of TLR4 mRNA expression levels after transfecting JJN3 cell line with TLR4 RNAi oligonucleotides or a non-targeting pool (siCtrl) for 48 h. (a2) Representative immunoblotting analyses of protein samples probed with an antibody against TLR4 after TLR4 RNAi for 48 h. (b1) % cell viability & (b2) % proliferation of JJN3 cells after TLR4 RNAi for 48 h. (c,d1) Q-PCR expression analyses of TLR4 mRNA expression levels after transfecting H929 (c) & U266 (d1) cell lines with the pCMV6-TLR4 construct or a pCMV6 empty vector for 48 h. (d2) Immunobloting analyses of U266 cells transfected with pCMV6-TLR4 or pCMV6 vector for 48 h; protein samples were probed with an antibody against TLR4. (e1) % cell viability & (e2) % proliferation of H929 & U266 cells after transfection with the pCMV6-TLR4 construct or with the empty pCMV6 vector for 48 h. beta -ACTIN probing & beta -ACTIN mRNA expression were used as reference for total protein & mRNA input, respectively. Cells transfected with the pCMV6-TLR4 construct are labelled as TLR4 OE (TLR4 overexpression), whereas cells transfected with the pCMV6 empty vector are labelled as Con (control). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241682147.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Regulation of FOXC1 on TLR expression. H9c2 cells were transfected with adenovirus or siRNA to overexpress or knock down FoxC1, with GFP adenovirus (Ad‐GFP) & negative control (NC) siRNA serving as control, respectively. A, FoxC1 overexpression increased Tlr3/4 mRNA & protein levels, under both control & ischaemic conditions. P values from the one‐way ANOVAs: <.001 (TLR3 mRNA), .002 (TLR4 mRNA), <.001 (FOXC1 mRNA), <.001 (TLR3 protein), <0.001 (TLR4 protein) & <.001 (FOXC1 protein). B, FoxC1 knockdown decreased Tlr3/4 mRNA & protein levels. P values from the one‐way ANOVAs: .001 (TLR3 mRNA), <.001 (TLR4 mRNA), <.001 (FOXC1 mRNA), .002 (TLR3 protein), <.001 (TLR4 protein) & <.001 (FOXC1 protein). C, FoxC1 overexpression up‐regulated the mRNA expression of multiple Tlr subtypes. P values from the one‐way ANOVAs: .022 (TLR1 mRNA), .047 (TLR2 mRNA), .002 (TLR3 mRNA), .013 (TLR4 mRNA), .039 (TLR5 mRNA), .003 (TLR6 mRNA), .203 (TLR7 mRNA), .078 (TLR8 mRNA) & .009 (TLR9 mRNA). Data are means ± SEM of 4 independent experiments. aP < .05, AP < .01 vs. control; bP < .05, BP < 0.01 vs. ischaemia Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31517441), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241552396.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Dasatinib affects TLR4 signaling to regulate LPS-induced proinflammatory cytokine levels in BV2 microglial cells. a BV2 microglial cells were pretreated with TAK-242 (a TLR4 receptor inhibitor, 500 nM) or vehicle (1% DMSO) for 30 min, treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min, & treated with LPS (1 μg/ml) or PBS for 5 h. The mRNA levels of COX-2 & IL-6 were analyzed by RT-PCR. b, c Quantification of the data in a (COX-2: con, n = 10; LPS, n = 10; dasatinib+LPS, n = 10; TAK-242+LPS, n = 10; TAK-242+dasatinib+LPS, n = 10; & IL-6: con, n = 14; LPS, n = 14; dasatinib+LPS, n = 14; TAK-242+LPS, n = 14; TAK-242+ dasatinib+LPS, n = 14). d BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 μg/ml) or PBS for 5.5 h, & cell surface biotinylation was conducted. e, f Quantification of the data in d (Surface TLR4: con, n = 11; LPS, n = 11; dasatinib+LPS, n = 11; Total TLR4: con, n = 16; LPS, n = 16; dasatinib+LPS, n = 16). One-way ANOVA with Tukey’s post hoc test was used to analyze significant differences. **p < 0.01, ***p < 0.001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31655606), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-3102024168390.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - (a1) Q-PCR assay of TLR4 mRNA expression levels after transfecting JJN3 cell line with TLR4 RNAi oligonucleotides or a non-targeting pool (siCtrl) for 48 h. (a2) Representative immunoblotting analyses of protein samples probed with an antibody against TLR4 after TLR4 RNAi for 48 h. (b1) % cell viability & (b2) % proliferation of JJN3 cells after TLR4 RNAi for 48 h. (c,d1) Q-PCR expression analyses of TLR4 mRNA expression levels after transfecting H929 (c) & U266 (d1) cell lines with the pCMV6-TLR4 construct or a pCMV6 empty vector for 48 h. (d2) Immunobloting analyses of U266 cells transfected with pCMV6-TLR4 or pCMV6 vector for 48 h; protein samples were probed with an antibody against TLR4. (e1) % cell viability & (e2) % proliferation of H929 & U266 cells after transfection with the pCMV6-TLR4 construct or with the empty pCMV6 vector for 48 h. beta -ACTIN probing & beta -ACTIN mRNA expression were used as reference for total protein & mRNA input, respectively. Cells transfected with the pCMV6-TLR4 construct are labelled as TLR4 OE (TLR4 overexpression), whereas cells transfected with the pCMV6 empty vector are labelled as Con (control). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30824741), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415532051.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - TLR4 expression in pVW-MSCs cultured with or without LPS (10 μg/ml) for 1 & 4 h & after additional 24 h of recovery after LPS removal (4hR). a: flow cytometry analysis were performed in not fixed & not permeabilized cells for TLR4 surface expression determination (TLR4: Surface) & in fixed & permeabilized cells to measure the overall TLR4 amount (TLR4: Total). Red histograms: stained cells; blue histograms: control cells. b: representative Western Blot of TLR4 & housekeeping beta -tubulin & relative quantification were presented. c: representative images of TLR4 immunostaining of pVW-MSCs cultured with or without LPS (10 μg/ml) for 4 h. pVW-MSCs nuclei were stained with Hoechst 33258 (blue). Scale bar = 10 μm. Data shown represent the mean ± SD of three biological replicates, each experiment is repeated three times. Data were analysed using one-way ANOVA followed by the Tukey’s post hoc comparison test. Different letters above the bars indicate significant differences (p < 0.05). (AU = Arbitrary Units) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31029157), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-3102024155457.jpg)
![Flow Cytometry: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - TLR4 expression in pVW-MSCs cultured with or without LPS (10 μg/ml) for 1 & 4 h & after additional 24 h of recovery after LPS removal (4hR). a: flow cytometry analysis were performed in not fixed & not permeabilized cells for TLR4 surface expression determination (TLR4: Surface) & in fixed & permeabilized cells to measure the overall TLR4 amount (TLR4: Total). Red histograms: stained cells; blue histograms: control cells. b: representative Western Blot of TLR4 & housekeeping beta -tubulin & relative quantification were presented. c: representative images of TLR4 immunostaining of pVW-MSCs cultured with or without LPS (10 μg/ml) for 4 h. pVW-MSCs nuclei were stained with Hoechst 33258 (blue). Scale bar = 10 μm. Data shown represent the mean ± SD of three biological replicates, each experiment is repeated three times. Data were analysed using one-way ANOVA followed by the Tukey’s post hoc comparison test. Different letters above the bars indicate significant differences (p < 0.05). (AU = Arbitrary Units) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31029157), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241552524.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Toll‐like receptor 4 (TLR4)‐shRNA lentivirus reduced myocardial inflammation & improved heart function after myocardial infarction (MI). The rats received intra‐myocardial injection of normal saline (NS), control‐shRNA lentivirus or TLR4‐shRNA lentivirus (1 × 109 TU/ml, 100 μl/heart) just after left anterior descending coronary artery (LAD) ligation or sham operation. All examinations were performed after 4 weeks of MI. (A) Expression of green fluorescent protein (GFP; green), the marker gene carried by TLR4‐shRNA lentivirus, in the myocardium. The nuclei were counter‐stained with Hoechst 33258 (blue). (B) Representative Western blot images & quantification of TLR4 proteins in sham & chronic heart failure (CHF) myocardium. (C) tumour necrosis factor (TNF)‐ alpha & interleukin (IL)‐6 protein contents in infarct & remote myocardium. (D) Representative images of Masson's trichrome staining (upper panel) & quantification (lower panel) of post‐infarct failing hearts, showing that TLR4‐shRNA lentivirus reduced cardiac fibrosis. Cross‐sections were cut at the midhorizontal plane of the fixed paraffin‐embedded heart, & stained with Masson's trichrome reagents. (E) Infarct size of post‐infarct failing hearts. (F) Fractional shortening (%) of the left ventricle (data are means ± SD, n = 4/group, aP < 0.05, AP < 0.01 versus respective sham‐NS; BP < 0.01 versus respective CHF‐NS). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26290459), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415523925.jpg)
![Western Blot: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - ALWPs significantly reduced LPS-induced cell-surface levels of TLR4. (A) BV2 microglial cells were pretreated with TAK-242 (a TLR4 inhibitor, 500 nM) for 30 min, followed by treatment with ALWPs (500 μg/ml) or PBS for 30 min & finally LPS (1 μg/ml) or PBS for 5 h. Total RNA was isolated, & IL-1 beta mRNA levels were measured by RT-PCR. (B) Quantification of the data from (A) (con, n = 20; LPS, n = 20; ALWPs + LPS, n = 20; TAK-242 + LPS, n = 20; TAK-242 + ALWPs + LPS, n = 20). (C) BV2 microglial cells were pretreated with ALWPs (500 μg/ml) or PBS for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h. Cell-surface biotinylation was then conducted with a TLR4 antibody recognizing the N-terminal region of TLR4. (D) Quantification of the data from (C) (Surface TLR4: con, n = 10; LPS, n = 10; ALWPs + LPS, n = 10; Total TLR4: con, n = 4; LPS, n = 4; ALWPs + LPS, n = 4). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30319390), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-310202415535173.jpg)
![Immunocytochemistry/ Immunofluorescence: TLR4 Antibody (76B357.1) - BSA Free [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. A) CRCs were separated into two groups representing low- & high- stromal expression of TLR4 by IHC staining. In normal tissue, stromal TLR4 expression is mainly due to macrophages (Green: TLR4, Red: CD68, Merge: TLR4 + CD68 + DAPI (blue)). Conversely, in CRCs increased vimentin & decreased CD68 staining in the pericryptal space confirm that this signal was due to pericryptal myofibroblasts & not related to tumor-associated macrophages. B) Double-stained immunofluorescence for TLR4 (green) & vimentin (red) in normal (I), adenoma (II), & colon adenocarcinoma (III) (10×). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. C) IHC staining of colon adenocarcinoma for TLR4, vimentin, & alpha -SMA (40×). Staining co-localizes to the pericryptal space, confirming the signal arises from pericryptal myofibroblasts. D, E, & F) An increase in IHC staining for alpha -SMA & vimentin was noted in CRCs when compared to normal or low grade dysplasia. A decrease in staining for CD68 positive macrophages was observed with higher degrees of dysplasia. Image collected & cropped by CiteAb from the following publication (//jeccr.biomedcentral.com/articles/10.1186/1756-9966-33-45), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56566_mouse-monoclonal-tlr4-antibody-76b357-1-imgenex-img-5031a-31020241612688.jpg)
![Western Blot: TNF-alpha Antibody [NBP1-19532] - Recombinant human TNF alpha (10 ng) was separated on a 12% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TNF alpha in 5% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody-Western-Blot-NBP1-19532-img0007.jpg "Western Blot: TNF-alpha Antibody [NBP1-19532] - Recombinant human TNF alpha (10 ng) was separated on a 12% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TNF alpha in 5% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Western Blot: TNF-alpha Antibody [NBP1-19532] - Scutellarin attenuates hypertension-induced brain expression of NF-kappaB, TNF-alpha, IL-1beta, and IL-18. Western immunoblot analysis for TNF-alpha in the rat cortex and striatum. Treatment with scutellarin significantly reduced the expression of these inflammatory markers in a dose-dependent manner. *P 0.05, not significant, * p < 0.05, ** p < 0.01. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36361925), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-19532_rabbit-polyclonal-tnf-alpha-antibody-immunohistochemistry-132202619354814.jpg)
![Immunohistochemistry: CD68/SR-D1 Antibody (KP1) [NB100-683] - Representative images (40x) of infiltrated macrophages stained with anti-CD 68 in the gingiva. The black arrowheads indicate the infiltrated macrophages. The right graphs show the quantitative data of CD68-positive cells in HPF (magnification of 200x). Data are expressed as the mean +/- SEM of three slides. *p<0.05 compared with control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0102450) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunohistochemistry-NB100-683-img0009.jpg "Immunohistochemistry: CD68/SR-D1 Antibody (KP1) [NB100-683] - Representative images (40x) of infiltrated macrophages stained with anti-CD 68 in the gingiva. The black arrowheads indicate the infiltrated macrophages. The right graphs show the quantitative data of CD68-positive cells in HPF (magnification of 200x). Data are expressed as the mean +/- SEM of three slides. *p<0.05 compared with control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0102450) licensed under a CC-BY license.")
![Flow Cytometry: CD68/SR-D1 Antibody (KP1) [NB100-683] - An intracellular stain was performed on THP-1 cells with CD68/SR-D1 Antibody NB100-683 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1:50 for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Flow-Cytometry-NB100-683-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: CD68/SR-D1 Antibody (KP1) [NB100-683] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD68/SR-D1 Antibody [KP1] (NB100-683) at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunocytochemistry-Immunofluorescence-NB100-683-img0012.jpg)
![Western Blot: CD68/SR-D1 Antibody (KP1) [NB100-683] - Total protein from mouse Raw cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-CD68 (NB100-683) in blocking buffer and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Western-Blot-NB100-683-img0007.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (KP1) [NB100-683] - An intracellular stain was performed on A431 cells with CD68/SR-D1 [KP1] Antibody NB100-683AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Flow-Cytometry-NB100-683-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CD68/SR-D1 Antibody (KP1) [NB100-683] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with CD68/SR-D1 Antibody [KP1] conjugated to Alexa Fluor 647 (NB100-683AF647) at 5 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunocytochemistry-Immunofluorescence-NB100-683-img0011.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (KP1) [NB100-683] - Analysis of a FFPE tissue section of human spleen using 1:200 dilution of CD68 antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Immunohistochemistry-Paraffin-NB100-683-img0006.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (KP1) [NB100-683] - An intracellular stain was performed on THP-1 cells with CD68 Antibody [KP1] NB100-683 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Flow-Cytometry-NB100-683-img0005.jpg)
![Dual RNAscope ISH-IHC: CD68/SR-D1 Antibody (KP1) [NB100-683] - NOS2 mRNA (red) and CD68 protein (green) were detected in formalin-fixed paraffin-embedded tissue sections of human breast cancer. ACD's Integrated Co-Detection Workflow was performed using ACD RNAScope Probe Hs-NOS2 and CD68/SR-D1 antibody (KP1) at 1:100 dilution. Tissue was stained on Leica Bond RX using RNAscope (TM) 2.5 LS Reagent Kit-RED, BOND Polymer Refine Detection (DAB) and Hematoxylin, BOND Polymer Refine Red Detection and Hematoxylin and RNAscope (TM) 2.5 LS Green Accessory Pack. Tissue was counterstained with 50% hematoxylin (blue).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-KP1-Dual-RNAscope-ISH-IHC-NB100-683-img0010.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0005.jpg "Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Analysis using the FITC conjugate of NB100-56726. Surface staining of stable HEK293/hTLR2 cells (IML-202, red) and vector control cells (IML-200, green) using TLR2 antibody at 1 ug/10^6 cells.")
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Expression of TLR2 was determined by western blotting. The immunoreactivity of the anti-TLR2 was confirmed with human intestinal lysate. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0015.jpg)
![Western Blot: TLR2 Antibody (TL2.1) [NB100-56722] - Total protein from human THP-1 and U937 cells was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-TLR2 (NB100-56722) in 5% BSA-TBST and detected with an anti-mouse HRP secondary antibody using NovaLume chemiluminescence detection reagent (NPB2-61915).](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Western-Blot-NB100-56722-img0016.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) [NB100-56722] - Monitoring of TLR2 expression in normal B cells and primary MCL cells cultured for 24h in the absence/presence of CD40L, IL-4, and TLR ligands. Filled curves refer to isotypic control, empty curves to the TLR2 antibody (NB100-56722) of untreated samples. Dotted histograms represent CD40L+IL4 activated cells, dashed curves indicate CD40L+IL4 activated cells further treated with TLR ligands. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0153823) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cytometry-NB100-56722-img0013.jpg)
![Flow (Cell Surface): TLR2 Antibody (TL2.1) [NB100-56722] - Flow (Cell Surface): - Azide Free [NB100-56726] - Analysis using the PE conjugate of NB100-56726. Staining of TLR2 on stable transfected cell line using this antibody at 1 ug/10^6 cells. Green: isotype control. Red: anti-TLR2 antibody. Image using the Azide Free form of this antibody.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Flow-Cell-Surface-NB100-56722-img0010.jpg)
![Block/Neutralize: TLR2 Antibody (TL2.1) [NB100-56722] - Human monocyte-derived DCs were pre-incubated wit TLR-neutralizing antibodies including TLR2 antibody (NB100-56722) for 1 h. Afterwards, DCs were infected with H. pylori G27 (MOI 5) and the levels of the costimulatory molecule CD86 and the maturation marker CD83 were analyzed by FACS on CD11c+ cells 24 h post-infection. Data are presented as mean +/- SD of five independent experiments. *p<=0.05, **p<=0.005, ***p<=0.0005. Asterisks on top of bars indicate significance relative to non-neutralized, H. pylori-primed control cells. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0104804) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TLR2-Antibody-TL2-1-Block-Neutralize-NB100-56722-img0014.jpg)
![Flow Cytometry: TLR2 Antibody (TL2.1) - BSA Free [NB100-56722] - Intracellular flow analysis of TLR2 in 1x10^6 PBMCs using 2 ug of NB100-56722. Shaded histogram represents cells without antibody; green represents isotype control; purple represents anti-TLR2 antibody.](http://images.novusbio.com/fullsize/nb100-56722_mouse-monoclonal-tlr2-antibody-tl2-1-17720241003212.jpg)
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Mouse spleen cryosection.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Immunohistochemistry-Paraffin-NBP2-33337-img0009.jpg "Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Mouse spleen cryosection.")
![Immunohistochemistry-Paraffin: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Mouse spleen.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Immunohistochemistry-Paraffin-NBP2-33337-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Wehi-3 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti CD68 (FA-11) [NBP2-33337] at a 1:100 dilution overnight at 4C and detected with an anti-rat DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Immunocytochemistry-Immunofluorescence-NBP2-33337-img0012.jpg)
![Flow (Intracellular): CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - An intracellular stain was performed on Raw 246.7 cells with CD68/SR-D1 (FA-11) antibody NBP2-33337 (blue) and a matched isotype control MAB006 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by DyLight488-conjugated anti-rat secondary antibody.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Flow-Intracellular-NBP2-33337-img0011.jpg)
![Western Blot: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Expression on J774 cells.](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Western-Blot-NBP2-33337-img0010.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - An intracellular stain was performed on Raw264.7 cells with CD68/SR-D1 Antibody (FA-11) NBP2-33337B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Flow-Cytometry-NBP2-33337-img0013.jpg)
![Flow Cytometry: CD68/SR-D1 Antibody (FA-11) [NBP2-33337] - Staining of permeabilised Mouse peritoneal Macrophages cells with Rat anti Mouse CD68 Antibody (Clone FA-11) visualised with F(ab')2 Goat Anti Rat IgG:FITC (Mouse Adsorbed).](http://images.novusbio.com/fullsize/CD68-SR-D1-Antibody-FA-11-Flow-Cytometry-NBP2-33337-img0007.jpg)
![TLR4 Inhibitor Peptide Set [NBP2-26244] - The inhibitor peptide inhibits TLR4 signaling by blocking interactions between TLR4 and its adaptors Mal/TIRAP and TRAM.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-NBP2-26244-img0013.jpg "TLR4 Inhibitor Peptide Set [NBP2-26244] - The inhibitor peptide inhibits TLR4 signaling by blocking interactions between TLR4 and its adaptors Mal/TIRAP and TRAM.")
![Blocking/Neutralizing: TLR4 Inhibitor Peptide Set [NBP2-26244] - iBMDM cultures were pretreated with 5uM of inhibitor or control prior to stimulation with 20 ng/ml LPS. Negative (LPS-, LPS-/CP7+, LPS-/CP7+) and positive (LPS+) controls were also included. Supernatants were harvested after 6 h and murine TNF-alpha measured by ELISA. TLR4 inhibitor, but not the control, inhibited LPS-induced TNF-alpha production. Image courtesy of Dr. Julianne Stack and Dr. Andrew Bowie, Trinity College, Dublin, Ireland.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26244-img0015.jpg)
![TLR4 Inhibitor Peptide Set [NBP2-26244] - TLR4/MD-2/CD14/NF-kB/SEAPorter stably transfected cells were plated in 96-well plates at 1x10^5 cells/well. After 16 h, cells were preincubated with various concentrations of inhibitor or control peptides (CP) for 1 h. Cells were then stimulated with 10 ng/ml LPS for 24 h. The secreted alkaline phosphatase (SEAP) was analyzed using the SEAPorter Assay Kit. Inhibitory effect on the LPS-mediated TLR4 activation by the VIPER peptide is shown in panel A, and IC50 of the VIPER peptide is described in panel B.](http://images.novusbio.com/fullsize/TLR4-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26244-img0016.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0011.jpg "Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed mRNA (B) and protein (D) production of NLRP3. Data are shown as mean +/- SD. **P < 0.01 vs sham group. Image collected and cropped by CiteAb from the following publication (//www.jneuroinflammation.com/content/12/1/137) licensed under a CC-BY license.")
![Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Staining of NALP3 in K562 cells with NALP3 antibody at 2 ug/mL.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0010.jpg)
![Immunohistochemistry-Paraffin: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in mouse lung tissue using anti-NALP3 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Immunohistochemistry-Paraffin-NBP1-77080-img0003.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Analysis of NALP3 in K562 cell lysate with NALP3 antibody at 1 ug/mL (A) in the absence and (B) in the presence of blocking peptide.](http://images.novusbio.com/fullsize/NLRP3-NALP3-Antibody---BSA-Free-Western-Blot-NBP1-77080-img0009.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. Representative image of immunofluorescent staining of NLRP3 related genes in corneal and conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/NLRP3-NALP3 Antibody - BSA Free-Immunocytochemistry-Immunofluorescence-NBP1-77080-img0012.jpg)
![Immunocytochemistry/ Immunofluorescence: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - hADSC-Evs suppressed NLRP3 inflammasome activation in ocular surface of experimental mice under desiccating stress. (A) Representative image of immunofluorescent staining of NLRP3 related genes in corneal & conjunctival epithelia of desiccating mice or treated with hADSC-EVs (*conjunctiva; open triangle cornea). (B,C) qRT-PCR showed the mRNA levels of NLRP3 related genes in conjunctiva & cornea (four corneas/conjunctivas were mixed as a sample). Data was shown as mean ± SEM. *p < 0.05. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32884023), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-31020241535675.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 promoted the activation of canonical NLRP3 inflammasome in retinal IR injury. The intravitreal injection of exogenous rHMGB1 significantly promoted the mRNA & protein production of NLRP3 (a, c) & ASC (e, g) & activation of caspase-1 (i). Thus, the intravitreal injection of HMGB1 inhibitor, GA, significantly suppressed the production of NLRP3 (b, d) & ASC (f, h) & activation of caspase-1 (j). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415345338.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - Co-immunoprecipitation assay: Figure showing interaction of NLRP3, NLRC4 & NAIP with ASC during CFT073 infection in THP-1m. Cytoplasmic extracts of THP-1m infected with or without CFT073, 6 h post stimulation were subjected to IP & WB by various antibodies (ASC, NLRP3, NLRC4, & NAIP) as described in material & methods. Cytoplasmic extract used as input was subjected to check NLRP3, ASC, NLRC4 & NAIP expression as shown in figure. ASC antibody was used to co-immunoprecipitate the complex from cytoplasmic extracts & then immunoblotted to detect NLRP3, NLRC4 & NAIP. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31551961), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415371971.jpg)
![Western Blot: NLRP3/NALP3 Antibody - BSA Free [NBP1-77080] - HMGB1 regulated the activation of NLRP3, rather than the activation of caspase-8, via NF-kappa B pathway. a, b NF-kappa B was activated in ischemic retina at the early stage after reperfusion. c, d Intraocular injection rHMGB1 or GA could promote or suppress the production of phosphor-NF-kappa B p65. e, f Intravitreal injection of NF-kappa B p65 inhibitor, JSH-23, significantly reduced the activation of NLRP3 & decreased the processing of IL-1 beta , g rather than caspase-8. However, intravitreal injection of caspase-8 inhibitor, Z-IETD-fmk, decreased the production of phosphor-NF-kappa B p65, obviously (h). Data are shown as mean ± SD. *P < 0.05, **P < 0.01 vs sham group Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26224068), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-77080_rabbit-polyclonal-nlrp3-nalp3-antibody-310202415291993.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse fore brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0020.jpg "Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse fore brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min")
![Immunocytochemistry/Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 Antibody (1 1:1000, Red) expression in dorsal root ganglia. Green fluorescent Nissl was used as counter-staining. Image submitted by a verified customer review.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-19019-img0002.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Mouse cerebellum stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0007.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat brain stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0010.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat cerebellum stained by AIF-1/Iba1 Antibody diluted at 1:500. Antigen Retrieval: Citrate buffer, pH 6.0, 15 min.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0011.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Rat hind brain. Iba1 antibody dilution: 1:500. Antigen Retrieval: Trilogy™ (EDTA based, pH 8.0) buffer, 15min](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0016.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - Analysis of paraffin-embedded human hepatoma, using at 1:500 dilution.Iba1 antibody detects AIF-1/Iba1 in the cytosol of Kupffer cell in human hepatoma by immunohistochemical analysis.](http://images.novusbio.com/fullsize/AIF-1-Iba1-Antibody-Immunohistochemistry-Paraffin-NBP2-19019-img0018.jpg)
![Immunohistochemistry: AIF-1/Iba1 Antibody [NBP2-19019] - LCN2 mainly expressed on neurons. a Representative immunofluorescence images of LCN2 (green) and AIF-1/Iba1 (red) staining in sections of the hippocampus after surgery. Long scale bar, 600 um; short scale bar, 25 um. Image collected and cropped by CiteAb from the following publication (pubmed.ncbi.nlm.nih.gov/35413913) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-2552023153956.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - LCN2 mainly expressed on neurons. a Representative immunofluorescence images of LCN2 (green), GFAP (red), NeuN (red) & IbaI (red) staining in sections of the hippocampus after surgery. Long scale bar, 600 µm; short scale bar, 25 µm. b Percentage quantification of LCN2 positive cells (n = 3 mice/group). c Cartoon depicting MACS sorting procedures for isolating CD11b+ & CD11b − cells. d Relative expression of cx3cr1 in CD11b + & CD11b − cells after sorting from all samples. d Relative expression level of Lcn2 mRNA in CD11b + & CD11b − cells from hippocampus 6 h after surgery. e Relative expression level of IL-6 mRNA in CD11b + cells. Data are represented as mean ± SEM. **** P Sample: Frozen-sectioned mouse brain.Green: AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Blue: Fluoroshield with DAPI .Antigen Retrieval: ice-cold MeOH for 5 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242091448.jpg)
![Western Blot: AIF-1/Iba1 Antibody [NBP2-19019] - Rat tissue extract (50 ug) was separated by 15% SDS-PAGE, and the membrane was blotted with AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:1000.](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242075976.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein by immunohistochemical analysis.Sample: Paraffin-embedded rat tissues.AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:100.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-910202420115036.jpg)
![Immunocytochemistry/ Immunofluorescence: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein at cell membrane by immunofluorescent analysis.Sample: THP-1 cells were fixed in 4% paraformaldehyde at RT for 15 min.Green: AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-91020242011504.jpg)
![Immunohistochemistry-Paraffin: AIF-1/Iba1 Antibody [NBP2-19019] - AIF-1/Iba1 antibody detects AIF-1/Iba1 protein at cell membrane and cytoplasm by immunohistochemical analysis.Sample: Paraffin-embedded mouse brain.AIF-1/Iba1 stained by AIF-1/Iba1 antibody (NBP2-19019) diluted at 1:500.Antigen Retrieval: Citrate buffer, pH 6.0, 15 min](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-910202419593534.jpg)
![Iba1 antibody detects Iba1 protein expression at microglias by immunohistochemical analysis.Sample: Frozen sectioned E13.5 Rat brain. Green: Iba1 protein stained by Iba1 antibody (NBP2-19019) diluted at 1:250.Red: beta Tubulin 3/ TUJ1, a mature neuron marker, stained by beta Tubulin 3/ TUJ1 antibody [GT11710] diluted at 1:500.Blue: Fluoroshield with DAPI .](http://images.novusbio.com/fullsize/nbp2-19019_rabbit-polyclonal-aif-1-iba1-antibody-immunohistochemistry-frozen-2611202518272320.jpg)
